Immunitybio sec filings
Witryna17 lis 2024 · More details about these and other risks that may impact ImmunityBio’s business are described under the heading "Risk Factors" in the Company’s Form 10-K filed with the U.S. Securities and ... Witryna14 kwi 2024 · Slide from corp presentation visualizing the overall strategy & vision. Important to highlight that they have a platform approach & are combining multiple agents. The first approv
Immunitybio sec filings
Did you know?
WitrynaThese reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Immunitybio Inc. Latest WitrynaSEC Filings. Date Filing Type Filing Description Download / View. 03.03.23. 4. Statement of Changes in Beneficial Ownership. 03.02.23. 144. Report of proposed sale of securities. 02.15.23.
Witryna20 mar 2024 · More details about these and other risks that may impact ImmunityBio’s business are described under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (“SEC”) on March 1, 2024 and in subsequent filings made by ImmunityBio with the SEC, … Witryna12 kwi 2024 · VISTA blocking immunotherapy engineered to address immunosuppression in the tumor microenvironment (TME) Phase 1 initial data readout anticipated by end of 2024 SEATTLE, April 12, 2024 — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel …
Witryna31 mar 2024 · Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934. Date of Report (Date of earliest event reported): March 31, 2024. ImmunityBio, Inc. … Witryna31 gru 2024 · SEC filings and transcripts for ImmunityBio Inc, including financials, news, proxies, indentures, prospectuses, and credit agreements ... Addition of …
Witryna13 kwi 2024 · ImmunityBio, Inc. SEC Filing - Quarterly Report (10-Q) August 08, 2024 SEC Filings Mon, Aug. 08, 2024 FDA accepts ImmunityBio's biologics license …
WitrynaGet the change in cash last 4y charts for Immunitybio (IBRX). 100% free, no signups. Get 20 years of historical change in cash last 4y charts for IBRX stock and other companies. Tons of financial metrics for serious investors. can i borrow against my 401k for houseWitrynaImmunityBio, Inc. Common Stock (IBRX) ... Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange … fitness factory gulf shores alWitryna0001193125-23-099195.txt : 20240412 0001193125-23-099195.hdr.sgml : 20240412 20240412160849 accession number: 0001193125-23-099195 conformed submission type: def 14a public document count: 8 conformed period of report: 20240525 filed as of date: 20240412 date as of change: 20240412 filer: company data: company … can i borrow against my 401k planWitryna10 kwi 2024 · Wealthcare Investment Partners, Llc (1908462) SEC Filing 13F-HR Institutional Manager Holdings Report for the period ending Friday, March 31, 2024 fitness factory lavalWitryna24 lut 2024 · ImmunityBio, Inc., a privately-held immunotherapy company, today announced the appointment of John Brennan, former Central Intelligence Agency … can i borrow against my 401k without penaltyWitryna13 kwi 2024 · SEC Filings Details. Document Details. Form: DEF 14A. Filing Date: Apr 13, 2024. Form Description: Proxy Statement (definitive) Filing Formats. Download PDF (opens in new window) Download DOC (opens in new window) Download XLS (opens in new window) Download ZIP (opens in new window) View HTML (opens in new … fitness factory las vegasWitrynaCellular Biomedicine Group, Inc. - SEC Filings - Registrant - CIK 1378624 - SEC fitness factory lightsview